Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –

Excerpt from the Press Release:

SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A. PENINSULA is the first Phase 2 outpatient trial to evaluate the role of a monoclonal antibody in the prevention of influenza A illness. The first participant was dosed in October 2022 and initial trial data are expected in mid-2023.

“We are experiencing the worst flu season in more than a decade, with at least 150,000 hospitalizations and 9,300 deaths from flu reported in the U.S. alone so far. These numbers emphasize the urgent need for additional preventive approaches against seasonal flu, especially for those at highest risk of hospitalization,” said Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research at Vir Biotechnology. “The rapid enrollment of the PENINSULA trial is a significant milestone that brings us one step closer to addressing the critical gap in preventing flu illness among those at high risk of serious illness. We look forward to reviewing the initial data to better understand whether a single shot of VIR-2482 has the potential to provide protection for the entire flu season.”

VIR-2482 is an intramuscularly administered investigational monoclonal antibody that has demonstrated in vitro the ability to neutralize all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic.

Click the button below to read the entire Press Release:

Continue Reading The Press Release